HK Stock Market Move | HENLIUS(02696) Surges Over 8% in Early Trading; HandaYuan Approved in Pakistan and Recently Included in the National Essential Medicines List

HENLIUS(02696) rose over 8% in early trading, up 8.56% as of press time, at HK$64.8, with a turnover of HK$20.1027 million. On the news front, recently, according to HENLIUS's official WeChat account, the company announced that its commercial partner Getz Pharma (Private) Limited ("Getz Pharma") has received the relevant registration certificate, and HandaYuan (adalimumab), independently developed and produced by HENLIUS, has been approved for marketing by the Drug Regulatory Authority of Pakistan (DRAP) under the trade name Adaliget, covering all local indications of the original adalimumab. HandaYuan has become HENLIUS's eighth product approved for overseas marketing, following products such as HanQuYou (trastuzumab, European trade name: Zercepac, U.S. trade name: HERCESSI), H drug HanSiZhuang (serplulimab, European trade name: Hetronifly), HanBeiYou (pertuzumab, European and U.S. trade name: Poherdy), and HanBeiTai (bevacizumab). HandaYuan was included in China's National Essential Medicines List (2026 Edition) in July 2026.